Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DMT210 in mild to moderate atopic dermatitis
NCT02949960Phase 2Completed
- Sponsor
- Dermata Therapeutics
- Start
- Oct 2016
- Primary completion
- Jul 2017
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of DMT210 in atopic dermatitis (AD), sponsored by Dermata Therapeutics. Started Oct 2016; status: completed.
02
Drugs
DMT210
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT02949960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02949960.